Insights & Discussion
Discover Related Insights
There is low quality evidence that bitter melon adjunct preparations improved glycemic control in type 2 diabetes mellitus patients.
2019 Journal of Ethnopharmacology Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: Systematic review and meta-analysis Peter EL, Kasali FM, Deyno S, Mtewa A, Nagendrappa PB, Tolo CU, et al.
Bitter Melon Type 2 Diabetes
Ten studies of type 2 diabetes mellitus (n = 1045) were included in the meta-analysis. They had 4–16 weeks follow up and overall moderate to high risk of bias. Compared to placebo, M. charantia monoherbal formulation significantly reduces FPG, PPG and HBA1c with mean difference of − 0.72 mmol/L, (95% CI: −1.33, −0.12), I2 = 14%, − 1.43 mmol/L, (95% CI: −2.18, −0.67), I2 = 0, − 0.26%, (95% CI: -0.49, −0.03), I2 = 0 respectively. M. charantia also lowered FPG in prediabetes (mean difference −0.31 mmol/L, n = 52); the evidence was downgraded to low quality because the study had unclear risk of bias and inadequate sample size. No serious adverse effects were reported.
M. charantia adjunct preparations improved glycemic control in T2DM patients. However, this conclusion is based on low to very low quality evidences for the primary outcomes and sparse data for several safety outcomes, thus, warrant further research. Particularly needed are the researches that focus on standardizing M. charantia formulation and determine its efficacy and safety in clinical trials with adequate sample size, designed with random sequence generation, allocation concealment of intervention and blinding of both research personnel and participants.